Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma

Bourantas, K., Economou, G. & Georgiou, J. (1997) Administration of high doses of recombinant human erythropoietin to patients with beta-thalassemia intermedia: a preliminary trial. European Journal of Haematology, 58, 22–25. Cermak, J. (2006) Erythropoietin administration may potentiate mobilization of storage iron in patients on oral iron chelation therapy. Hemoglobin, 30, 105–112. Fortenko, O.M., Schaef Johns, G.J. & Kudva, G.C. (2009) Erythropoietin for hemoglobin H disease. Annals of Hematology, 88, 179–180. Galanello, R., Barella, S., Turco, M.P., Giagu, N., Cao, A., Dore, F., Liberato, N.L., Guarnone, R. & Barosi, G. (1994) Serum erythropoietin and erythropoiesis in highand low-fetal hemoglobin beta-thalassemia intermedia patients. Blood, 83, 561–565. Maccio, A., Madeddu, C., Chessa, P., Mantovani, G. & Galanello, R. (2009) Use of erythropoiesis stimulating agents for the treatment of anaemia and related fatigue in a pregnant woman with HbH disease. British Journal of Haematology, 146, 335–337. Meo, A., Cassinerio, E., Castelli, R., Bignamini, D., Perego, L. & Cappellini, M.D. (2008) Effect of hydroxyurea on extramedullary haematopoiesis in thalassaemia intermedia: case reports and literature review. International Journal of Laboratory Hematology, 30, 425–431. O’Donnell, A., Premawardhena, A., Arambepola, M., Allen, S.J., Peto, T.E., Fisher, C.A., Rees, D.C., Olivieri, N.F. & Weatherall, D.J. (2007) Agerelated changes in adaptation to severe anemia in childhood in developing countries. Proceedings of the National Academy of Sciences of the United States of America, 104, 9440–9444. Perrine, S.P. (2005) Fetal globin induction–can it cure beta thalassemia? Hematology American Society of Hematology. Education Program, 38–44. Rachmilewitz, E.A., Aker, M., Perry, D. & Dover, G. (1995) Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous beta-thalassaemia. British Journal of Haematology, 90, 341–345. Sukpanichnant, S., Opartkiattikul, N., Fucharoen, S., Tanphaichitr, V.S., Hasuike, T. & Tatsumi, N. (1997) Difference in pattern of erythropoietin response between beta-thalassemia/hemoglobin E children and adults. Southeast Asian Journal of Tropical Medicine and Public Health, 28(Suppl 3), 134–137.

[1]  C. Gisselbrecht,et al.  The impact of pre‐ and post‐transplantation positron emission tomography using 18‐fluorodeoxyglucose on poor‐prognosis lymphoma patients undergoing autologous stem cell transplantation , 2007, Cancer.

[2]  Yuan Ji,et al.  Dose-finding in phase I clinical trials based on toxicity probability intervals , 2007, Clinical trials.

[3]  E. Vellenga,et al.  Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. , 2007, Blood.

[4]  O. Sezer,et al.  Bortezomib Is Not Active in Patients with Relapsed Hodgkin’s Lymphoma: Results of a Prematurely Closed Phase II Study. , 2006 .

[5]  B. Cheson,et al.  A phase II study of bortezomib in relapsed Hodgkin lymphoma: Preliminary results of CALGB 50206. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Lister,et al.  Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Younes,et al.  Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. , 2006, Blood.

[8]  B. Aggarwal,et al.  Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-κB Mutations or Activation of the CD30, CD40, and RANK Receptors , 2004, Clinical Cancer Research.

[9]  A. Zelenetz,et al.  A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. , 2001, Blood.